July 01, 2026
Colorado is preliminarily blocked from enforcing its price cap on Amgen's rheumatoid arthritis drug Enbrel, a federal judge ruled Wednesday, saying the biotech company is likely to succeed on its claim that federal patent law preempts the state's effort to limit the price of patented medications.
November 04, 2025
In a flurry of recent legal activity, courts across the country have been drawn into the nation's most contentious healthcare debates over access to medication abortions and efforts to cap the cost of prescription medications.
October 31, 2025
Amgen has once again sued Colorado over its price cap for the arthritis drug Enbrel, claiming that the Centennial State's drug price-control statute violates the U.S. Constitution, conflicts with federal patent law and threatens patients' access to lifesaving medications.